Patients whose aggressive lymphomas have relapsed or failed to respond to the current front-line chemotherapy regimen now have an effective second line of attack against their disease.
Reporting the results of a first-of-its-kind phase 1 clinical trial to test the effectiveness of a new class of drugs to augment standard chemotherapy, a team led by Fred Hutch researchers found that giving patients high doses of Vorinostat (suberoylanilide hydroxamic acid) in combination with another round of commonly used second-line drugs resulted in a 70 percent response rate, including several patients whose lymphoma cells disappeared entirely.
According to Fred Hutch’s Dr. Ajay Gopal, a corresponding author of the paper published online in the British Journal of Haematology, the study results open the way to potentially solve the dilemma of how to effectively treat patients when modern cancer drugs fail after the first try.
And, he said, it sets the stage for using a new class of drugs called histone-deacetylase inhibitors (HDAC), such as Vorinostat, to sensitize tumor cells to the cancer-killing effects of chemotherapy.
Patients treated in the trial had several types of lymphoma, however the best responses were seen in those who had Hodgkin and diffuse large B-cell lymphomas, two of the most aggressive types that typically require a stem cell transplant to cure if they are not cured after the first line of treatment. Knocking back the cancer raises the likelihood for a successful transplant.
“The better the response, the better the outcome will be when patients proceed to a stem cell transplant designed to cure them of their disease,” said Fred Hutch’s Dr. Elizabeth Budde, first author of the study.